What Analysts Estimate for General Maritime Partners’ 1Q17 Results
Wall Street analysts estimate that General Maritime Partners’ (GNRT) revenue will be ~$116 million in the first quarter compared with $99 million in 4Q16 and ~$121.6 million in 1Q16.
Euronav’s (EURN) CEO, Paddy Rogers, discussed his thoughts on the outlook for the tanker industry at a recent shipping conference.
Frontline’s (FRO) stock hasn’t had a good run in 2017. The stock reached its 52-week low of $6.61 on April 5, 2017.
DHT Holdings’ (DHT) stock price closed at $4.65 on April 24, 2017, which is 6.2% higher than its price six months ago.
Wall Street analysts estimate that Tsakos’s revenue will be ~$113 million in 1Q17 compared with $130 million in 4Q16 and ~$122 million in 1Q16.
Nordic American Tankers (NAT) plans to release its 1Q17 earnings on Monday, May 8, 2017, before the market opens.
Wall Street analysts estimate that Teekay Tankers’ (TNK) revenue will be ~$102 million in the first quarter compared with $117.9 million in 4Q16 and ~$164.9 million in 1Q16.
On April 24, 2017, Navios Maritime Midstream Partners (NAP) declared a cash dividend of $0.42 per unit for the first quarter of 2017.
In this series, we’ll look at Wall Street analysts’ recommendations and ratings for crude tanker companies.
National Oilwell Varco (NOV) released its financial results for 1Q17 on April 26, and its stock price rose ~1% to $36.15 that day.
On April 26, after NOV’s 1Q17 earnings were released, ~17% of the analysts tracking it rated the stock as a “buy,” while about 74% rated it as a “hold.”
From 1Q16 to 1Q17, the Rig Systems segment’s revenue fell ~58%—the highest revenue drop among NOV’s operating segments.
National Oilwell Varco (NOV) recorded total revenues of ~$1.7 billion in 1Q17, which was 20.5% lower than the ~$2.2 billion it recorded in 1Q16.
In 1Q17, Amgen’s (AMGN) Enbrel witnessed a fall in unit demand, in line with the trend witnessed in 2016.
In 1Q17, Amgen’s (AMGN) Prolia continued to be a dominant player in the bone health segment. Indicated for postmenopausal osteoporosis, the drug managed to gain market share across all geographies in 1Q17.
On March 3, 2017, Amgen announced positive results from its Phase 3 trial 482 study evaluating the efficacy of Xgeva in delaying skeletal-related events or bone complications in multiple myeloma patients.
On March 3, 2017, Amgen (AMGN) presented interim data from its Phase 3 trial, ENDEAVOR. The data showed the superiority of a combination therapy of Kyprolis and dexamethasone over Velcade.
Amgen (AMGN) expects its strategy to launch innovative therapies with differentiated modes of action in disease areas with significant unmet demand to be a key growth driver for its share price in future years.
In 1Q17, Amgen’s (AMGN) PCSK9 inhibitor therapy, Repatha, reported revenue of nearly $49 million. The drug earned $33 million in revenue in US markets and $16 million in international revenue.
In 1Q17, Amgen (AMGN) reported revenue of ~$5.5 billion, a year-over-year (or YoY) fall of ~1.1%. This fall can mainly be attributed to a fall of ~0.7% in the company’s product sales in 1Q17.